Biotech Values

[DewDiligence]

Roche reports PFS from phase-3 in first-line non-squamous NSCLC:

https://www.roche.com/media/store/releases/med-cor-2017-11-20.htm

Roche…today announced that the Phase III IMpower150 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ…and Avastin…plus chemotherapy (paclitaxel and carboplatin) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death (PFS) compared to Avastin plus chemotherapy in the first-line treatment of people with advanced non-squamous non-small cell lung cancer (NSCLC).

Initial observations for the co-primary endpoint of overall survival (OS) are encouraging. These data are not fully mature and the next OS analysis is expected in the first half of 2018.

The full dataset (with the OS data still immature) will be reported at ESMO in December.

Not disclosed in today’s PR: How patients performed in the Tecentriq + chemo (without Avastin) trial arm.